Despite encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable opposition from pharmacy benefit managers. These organizations are often creating obstacles to access, such as high cost criteria and approval processes that hinder consumer availability. Analysts